SBPH | tickerfilter.com

Fundamental analysis

49%

Profitability 50%

Dept financing 50%

Liquidity 40%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$1.21

P/E Ratio

N/A

DAY RANGE

$1.21 - $1.21

EPS

-$1.64

52 WEEK RANGE

$0.80 - $4.80

52 WEEK CHANGE

-$60.07

MARKET CAP

20.893 M

YIELD

N/A

SHARES OUTSTANDING

17.267 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

$15,902,729

AVERAGE 10 VOLUME

$64,833

AVERAGE 30 VOLUME

$55,177

Company detail

CEO: Martin J. Driscoll
Region: US
Website: http://www.springbankpharm.com
Employees: 30
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

SBPH - Spring Bank Pharmaceuticals Inc.